The DOI matches its Crossref record.
Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)
Abstract
Background: Alterations in the fibroblast growth factor receptor 3 (FGFR3) have been identified as oncogenic drivers in several solid tumor malignancies, including urothelial carcinoma (UC). Available pan-FGFR inhibitors target all 4 isoforms of FGFR (FGFR1 - 4) and consequently their efficacy can be limited by off-target toxicity (i.e. inhibition of other non-altered FGFR isoforms) including gastrointestinal, oral mucositis, and cutaneous/nail disorders, as well as FGFR1-mediated hyperphosphatemia. Moreover, clinical studies of pan-FGFR inhibitors have reported the development of drug resistance through acquired gatekeeper mutations (e.g. V555M and V565F) at the time of disease progression. LOXO-435 is a potent, highly isoform-selective FGFR3 inhibitor that is designed to preserve activity in the setting of gatekeeper resistance mutations. Preclinically, LOXO-435 has demonstrated potent in vitro and in vivo activity as a selective inhibitor of both wild-type and oncogenically activated FGFR3, including FGFR3 fusions, point mutations, and acquired gatekeeper resistance mutations without evidence of FGFR1-mediated hyperphosphatemia. Methods: LOXO-FG3-22001 is a multicenter, open-label, first-in-human phase 1a/b study of LOXO-435 in patients (pts) with FGFR3-altered advanced solid tumors, including metastatic UC (mUC) (NCT05614739). Eligible pts (≥ 18 years) must have an advanced or metastatic solid tumor with an FGFR3 alteration detected in tumor or ctDNA, ECOG PS of 0-1, and have received all standard therapy or have no known available options to provide benefit. The study will be conducted in 2 phases: phase 1a dose escalation and phase 1b dose expansion. Dose escalation (cohort A) will begin as a single-patient accelerated design, allowing intra-patient dose escalation, followed by the modified toxicity probability interval-2 method. Additional pts will be allowed to backfill to previously cleared dose levels that demonstrate therapeutically relevant exposures or direct evidence of clinical activity. Dose escalation will assess safety, PK/PD, and antitumor activity of LOXO-435 as monotherapy to determine the recommended phase 2 dose (RP2D). Dose expansion will include 4 cohorts of pts with prespecified activating FGFR3 alterations. Cohort B will enroll pts with mUC and include 2 cohorts to evaluate LOXO-435 as monotherapy (B1, B2) and 1 cohort to evaluate LOXO-435 in combination with pembrolizumab (B3). Cohort C will enroll pts with non-UC advanced solid tumors and will evaluate LOXO-435 as monotherapy (C1). Pts in cohort B1 must have progressed on or were intolerant to a prior FGFR inhibitor, and pts in cohorts B2, B3, and C1 must be FGFR inhibitor treatment naive. Dose expansion will evaluate the safety, PK/PD, and antitumor activity (per RECIST v1.1) of LOXO-435 at the RP2D. Citation Format: Gopa Iyer, Arlene Siefker-Radtke, Matthew Milowsky, Neal Shore, Xin Gao, Melissa A. Reimers, Noah Hahn, Rasha Cosman, Nobuaki Matsubara, Andrea Necchi, Debbie Robbrecht, Armelle Vinceneux, Enrique Grande, Jae-Lyun Lee, Tian Zhang, Tormod Guren, Ulrich M. Lauer, Michal Sarfaty, Bernhard Eigl, Syed Hussain, Xiang Zhao, Arjun V. Balar, Kaitlyn Francese, Ryan Widau, Benjamin Garmezy. A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT119.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, isoform-selective FGFR3 inhibitors (e.g., LOXO-435) are under clinical investigation.65”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [65]
Citations
Cites
Still being checked.
Cited by
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Katoh, M., Loriot, Y., Brandi, G., Tavolari, S., Wainberg, Z. A., & Katoh, M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00869-z · Cited by 195
Hudkins, R. L., Allen, E., Balcer, A., Hoffman, I., Iyer, S., Neal, M., Nelson, K. J., Rideout, M., Ye, Q., Starrett, J. H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01531 · Cited by 38
Necchi, A., Pouessel, D., Leibowitz‐Amit, R., Gupta, S., Fléchon, A., García-Donás, J., Bilen, M. A., Debruyne, P. R., Milowsky, M. I., Friedlander, T. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.794 · Cited by 36
Self-citationPatel, D., Mateen, R., Qaddour, N., CARRILLO, A. C., Verschraegen, C. F., Yang, Y., Li, Z., Sundi, D., Mortazavi, A., & Collier, K. A. (2024) · Cancers · doi:10.3390/cancers16020335 · Cited by 26
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer
Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.10.010 · Cited by 23
Metadata
- Authors
- Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., Robbrecht, D., Vinceneux, A., Grande, E., Lee, J.-L., Zhang, T., Guren, T., Lauer, U. M., Sarfaty, M., Eigl, B., Hussain, S., Zhao, X., Balar, A. V., Francese, K., Widau, R., & Garmezy, B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Carolina Urologic Research Center (US)
- Massachusetts General Hospital (US)
- Washington University in St. Louis (US)
- Johns Hopkins University (US)
- UNSW Sydney (AU)
- 9National Cancer Center Hospital East, Chiba, Japan;
- IRCCS Ospedale San Raffaele (IT)
- Erasmus MC Cancer Institute (NL)
- Centre Léon Bérard (FR)
- MD Anderson Cancer Center Madrid (ES)
- Asan Medical Center (KR)
- The University of Texas Southwestern Medical Center (US)
- Oslo University Hospital (NO)
- Universitätsklinikum Tübingen (DE)
- Tel Aviv University (IL)
- BC Cancer Agency (CA)
- University of Sheffield (GB)
- 21Loxo@Lilly, Indianapolis, IN;
- Sarah Cannon (US)
- ORCID
- Iyer, Gopa
- Siefker-Radtke, Arlene
- Milowsky, Matthew
- Shore, Neal
- Gao, Xin
- Reimers, Melissa A.
- Hahn, Noah
- Cosman, Rasha
- Matsubara, Nobuaki
- Necchi, Andrea
- Robbrecht, Debbie
- Vinceneux, Armelle
- Grande, Enrique
- Lee, Jae-Lyun
- Zhang, Tian
- Guren, Tormod
- Lauer, Ulrich M.
- Sarfaty, Michal
- Eigl, Bernhard
- Hussain, Syed
- Zhao, Xiang
- Balar, Arjun V.
- Garmezy, Benjamin
- Venue
- Cancer Research
- Published
- 2023-04-14
- Volume
- 83
- Issue
- 8_Supplement
- Pages
- CT119-CT119
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W4365512324
- Semantic Scholar
- 2c3d4b85410531044098f001b0292534b5a470f0
- Cited by
- 12
- References
- 0
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 3 · 2023: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- FGFR3 inhibitors, FGFR3 alterations, metastatic urothelial carcinoma, advanced solid tumors, gatekeeper mutation, FGFR3 fusion, dose escalation, anticancer activity, acquired drug resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress). https://app.cochat.ai/papers/10.1158/1538-7445.am2023-ct119
- The paper
- Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., Robbrecht, D., Vinceneux, A., Grande, E., Lee, J.-L., Zhang, T., Guren, T., Lauer, U. M., Sarfaty, M., Eigl, B., . . . Garmezy, B. (2023). Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress). Cancer Research. https://doi.org/10.1158/1538-7445.am2023-ct119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.